Liver mesenchymal stem cells are superior inhibitors of NK cell functions through differences in their secretome compared to other mesenchymal stem cells.
immune regulation
immunomodulation
liver transplant
mesenchymal stem cells
tolerance
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2022
2022
Historique:
received:
24
05
2022
accepted:
07
09
2022
entrez:
10
10
2022
pubmed:
11
10
2022
medline:
12
10
2022
Statut:
epublish
Résumé
Liver-resident mesenchymal stem cells (L-MSCs) are superior inhibitors of alloreactive T cell responses compared to their counterparts from bone marrow (BM-MSCs) or adipose tissue (A-MSCs), suggesting a role in liver's overall tolerogenic microenvironment. Whether L-MSCs also impact NK cell functions differently than other MSCs is not known. We generated and characterized L-MSCs, A-MSCs and BM-MSCs from human tissues. The mass spectrometry analysis demonstrated that L-MSC secretome is uniquely different than that of A-MSC/BM-MSC, with enriched protein sets involved in IFNγ responses and signaling. When co-cultured with primary human NK cells, L-MSCs but not other MSCs, decreased surface expression of activating receptors NKp44 and NKG2D. L-MSCs also decreased IFNγ secretion by IL-2-stimulated NK cells more effectively than other MSCs. Cytolytic function of NK cells were reduced significantly when co-cultured with L-MSCs, whereas A-MSCs or BM-MSCs did not have a major impact. Mechanistic studies showed that the L-MSC-mediated reduction in NK cell cytotoxicity is not through changes in secretion of the cytotoxic proteins Perforin, Granzyme A or B, but through increased production of HLA-C1 found in L-MSC secretome that inhibits NK cells by stimulating their inhibitory receptor KIRDL2/3. L-MSCs are more potent inhibitors of NK cell functions than A-MSC or BM-MSC. Combined with their T cell inhibitory features, these results suggest L-MSCs contribute to the tolerogenic liver microenvironment and liver-induced systemic tolerance often observed after liver transplantation.
Identifiants
pubmed: 36211345
doi: 10.3389/fimmu.2022.952262
pmc: PMC9534521
doi:
Substances chimiques
Interleukin-2
0
NK Cell Lectin-Like Receptor Subfamily K
0
Perforin
126465-35-8
Granzymes
EC 3.4.21.-
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
952262Informations de copyright
Copyright © 2022 Yigitbilek, Ozdogan, Abrol, Park, Hansen, Dasari, Stegall and Taner.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Biochem Biophys Res Commun. 2007 Sep 28;361(3):745-50
pubmed: 17678624
Front Behav Neurosci. 2016 Mar 11;10:46
pubmed: 27014007
Front Immunol. 2020 Jul 23;11:1454
pubmed: 32793200
Stem Cell Res Ther. 2021 Feb 17;12(1):138
pubmed: 33597011
Hepatology. 2014 Dec;60(6):2109-17
pubmed: 24913836
Am J Transplant. 2016 Jun;16(6):1653-80
pubmed: 26848550
Cytotherapy. 2006;8(4):315-7
pubmed: 16923606
PLoS Genet. 2015 Aug 20;11(8):e1005439
pubmed: 26292085
Kidney Int. 2017 May;91(5):1193-1202
pubmed: 28233612
Front Immunol. 2019 Nov 19;10:2667
pubmed: 31803188
Annu Rev Immunol. 2001;19:197-223
pubmed: 11244035
J Stem Cells Regen Med. 2019 May 30;15(1):1-2
pubmed: 31239604
Nat Rev Gastroenterol Hepatol. 2018 Sep;15(9):555-567
pubmed: 29844586
Stem Cells. 2014 Jun;32(6):1408-19
pubmed: 24578244
World J Gastroenterol. 2019 Jul 7;25(25):3123-3135
pubmed: 31333306
NPJ Regen Med. 2019 Apr 16;4:8
pubmed: 31016031
Stem Cells Dev. 2019 Jan 1;28(1):44-55
pubmed: 30328799
Front Immunol. 2020 Jun 05;11:1044
pubmed: 32582167
J Stem Cells Regen Med. 2019 May 30;15(1):8-11
pubmed: 31239606
Exp Hematol. 1974;2(2):83-92
pubmed: 4455512
Front Immunol. 2019 Nov 15;10:2663
pubmed: 31849929
Transplantation. 2021 Feb 1;105(2):284-290
pubmed: 32384380
Cell Stem Cell. 2012 May 4;10(5):544-55
pubmed: 22542159
Genomics. 2020 Sep;112(5):3615-3623
pubmed: 32353479
Cells. 2019 Aug 13;8(8):
pubmed: 31412678
Blood. 2008 Feb 1;111(3):1327-33
pubmed: 17951526
Blood. 2006 Feb 15;107(4):1484-90
pubmed: 16239427
Kidney Int. 2018 Jun;93(6):1465-1474
pubmed: 29656904
Nat Rev Gastroenterol Hepatol. 2020 Dec;17(12):719-739
pubmed: 32759983
Cytotherapy. 2013 Sep;15(9):1054-61
pubmed: 23602578
Am J Physiol Gastrointest Liver Physiol. 2008 Apr;294(4):G1070-7
pubmed: 18292182
J Immunol. 1986 Jun 15;136(12):4480-6
pubmed: 3086432
Front Immunol. 2015 Nov 03;6:560
pubmed: 26579133
Kidney Int. 2016 Apr;89(4):909-17
pubmed: 26924059
Stem Cells Dev. 2012 Sep 20;21(14):2724-52
pubmed: 22468918
Liver Transpl. 2020 Apr;26(4):549-563
pubmed: 31950576
Trends Immunol. 2001 Nov;22(11):633-40
pubmed: 11698225
Gut. 2003 Feb;52(2):307-14
pubmed: 12524419
Bone Marrow Transplant. 2003 Aug;32(3):265-72
pubmed: 12858197
Hum Immunol. 2020 Aug;81(8):423-429
pubmed: 32546429
J Stem Cell Regen Biol. 2017;3(2):
pubmed: 29104965
Blood. 2005 Feb 15;105(4):1815-22
pubmed: 15494428
Mol Cell Proteomics. 2014 Sep;13(9):2513-26
pubmed: 24942700
PLoS One. 2011;6(5):e19988
pubmed: 21625521
Nat Med. 2009 Jan;15(1):42-9
pubmed: 19098906
Int J Mol Sci. 2017 Aug 25;18(9):
pubmed: 28841158
Cell Rep. 2017 Sep 19;20(12):2891-2905
pubmed: 28930684
World J Stem Cells. 2019 Jun 26;11(6):347-374
pubmed: 31293717
Biomaterials. 2019 Mar;196:67-79
pubmed: 29602560
Hypertension. 2020 May;75(5):1223-1232
pubmed: 32223383
Am J Transplant. 2016 Dec;16(12):3522-3531
pubmed: 27184686
Transplantation. 1974 Apr;17(4):331-40
pubmed: 4150881